Marijuana abuse
Drug research and approvals for marijuana abuse: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 84 studies of marijuana abuse are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 84
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Naturally Produced Cannabinoids for Neuroprotection From ConcussionNCT07715864 · Phase 2 · University of Regina · starts Jun 1, 2026
- Cannabis Observations on Brain Waves, Retrieval, and Attention: Experiment 4NCT07679581 · Not reported · L. Cinnamon Bidwell · starts Dec 10, 2025
- Challenging the Endocannabinoid System in Sleep Restricted Healthy Volunteers to Modulate Physiological Arousal…NCT07656350 · Not applicable · King's College London · starts Jun 2, 2026
- Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use DisorderNCT07644052 · Phase 3 · PleoPharma, Inc. · starts Jun 17, 2026
- The Pharmacokinetics of a Hemp-Based Topical ProductNCT07603518 · Phase 1 · Johns Hopkins University · starts May 26, 2026
- Cannabidiol for Pain Relief of Patients With End-stage mCRPCNCT07549256 · Phase 2 · Regionshospital Nordjylland · starts Jun 12, 2026
- Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use DisorderNCT07523633 · Phase 2 · Anders Fink-Jensen, MD, DMSci · starts Apr 30, 2026
- Feasibility and Acceptability Trial to Reduce Tobacco and Cannabis Use During Pregnancy and PostpartumNCT07489443 · Not applicable · University of Pittsburgh · starts Jun 17, 2026
- Psychiatric Symptom Characteristics in Methamphetamine-Induced Psychosis With and Without Lifetime Cannabis UseNCT07459270 · Not reported · Elazığ Mental Health and Diseases Hospital · starts Mar 16, 2026
Phase 3 3
- Cannabinol
- AcetylcysteineGlutathione precursor
- NicotineNeuronal acetylcholine receptor; alpha4/beta2 agonist
Phase 2 12 of 26
- DronabinolCannabinoid CB1 receptor agonist
- CannabidiolCannabinoid CB1 receptor negative allosteric modulator
- NaltrexoneOpioid receptors; mu/kappa/delta antagonist
- QuetiapineSerotonin 2a (5-HT2a) receptor antagonist
- BaclofenGABA-B receptor agonist
- BupropionDopamine transporter inhibitor
- ProgesteroneProgesterone receptor agonist
- BuspironeSerotonin 1a (5-HT1a) receptor partial agonist
- GuanfacineAdrenergic receptor alpha-2 agonist
- AprepitantNeurokinin 1 receptor antagonist
- NabiloneCannabinoid CB1 receptor agonist
- GabapentinVoltage-gated calcium channel modulator
Phase 1 or earlier 11
- LorcaserinSerotonin 2c (5-HT2c) receptor agonist
- KetamineGlutamate [NMDA] receptor negative allosteric modulator
- Alcohol
- EszopicloneGABA-A receptor; anion channel positive allosteric modulator
- ZolpidemGABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator
- RimonabantCannabinoid CB1 receptor antagonist
- RamelteonMelatonin receptor agonist
- Yohimbine
- Delta-8-tetrahydrocannabinol
- Selonabant
- PregabalinVoltage-gated calcium channel modulator
How its trials ended
467 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 71 whose ending is known, 39% met their primary endpoint, 10% missed it and 51% stopped early.
- Completed, result not reported23751%
- Ongoing11825%
- Status unknown419%
- Met its primary endpoint286%
- Stopped: other or unclear235%
- Missed its primary endpoint71%
- Stopped: enrollment or feasibility61%
- Stopped: sponsor or business decision41%
- Stopped: funding2<1%
- Stopped: lack of efficacy1<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA